Theravance Biopharma's market cap is currently ―. The company's EPS TTM is $-0.97; its P/E ratio is -9.29; Theravance Biopharma is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.25. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 15.69M	$ 13.75M	$ 10.41M	$ 14.65M	$ 12.45M
Gross Profit	$ 15.69M	$ 13.75M	$ 10.42M	$ 14.65M	-
EBIT	$ -6.97M	$ -13.62M	$ -21.93M	$ -61.89M	$ -14.48M
EBITDA	-	-	$ -20.95M	$ -59.86M	$ -13.16M
Net Income Common Stockholders	$ -8.95M	$ -21.91M	$ -29.51M	$ -17.31M	$ 916.63M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 134.00M	$ 167.45M	$ 241.26M	$ 327.48M	$ 486.83M
Total Assets	$ 413.59M	$ 446.63M	$ 538.55M	$ 607.40M	$ 763.50M
Total Debt	$ 50.83M	$ 51.68M	$ 51.19M	$ 52.16M	$ 52.07M
Net Debt	$ -83.17M	$ -115.77M	$ -190.07M	$ -275.32M	$ -434.76M
Total Liabilities	$ 167.46M	$ 166.47M	$ 167.99M	$ 165.60M	$ 282.92M
Stockholders Equity	$ 246.13M	$ 280.16M	$ 370.56M	$ 441.80M	$ 480.58M
Cash Flow	-
Free Cash Flow	-	-	$ -11.95M	$ 54.65M	$ -22.08M
Operating Cash Flow	$ -2.49M	$ -12.44M	$ -11.22M	$ 54.91M	$ -22.14M
Investing Cash Flow	$ -21.00K	$ 11.05M	$ -43.05M	$ 39.16M	$ 1.08B
Financing Cash Flow	$ -31.40M	$ -80.68M	$ -56.24M	$ -35.47M	$ -722.03M

Currency in USD

Theravance Biopharma Earnings and Revenue History

Income Statement >

Theravance Biopharma Debt to Assets

Balance Sheet >

Theravance Biopharma Cash Flow

Cash Flow >

Theravance Biopharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing